Tag Archives: FDA

SCYNEXIS Partnering with Amplity Health to Launch BrexafemmeTM

SCYNEXIS announced that it has partnered with Amplity Health, a leading global contract commercialization organization, to support the anticipated U.S. commercialization of Brexafemme

JNJ’s Multiple Sclerosis Drug Ponvory Available From Covance Specialty Pharmacy

The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced that the FDA approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS). PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven […]

PharMerica’s Onco360 Selected as Exclusive Specialty Pharmacy Partner for UKONIQ

PharMerica is a leading provider of home and community-based health and pharmacy services for high-need and medically complex populations

Eton Pharmaceuticals’ ALKINDI® SPRINKLE is available exclusively through AnovoRx

AnovoRx’s focus is intentionally centered on the unique needs of patients with chronic diseases who rely on specialty and orphan drugs as well as manufacturers

Centene Strengthens Specialty Pharmacy Rare Disease Position with PantherRx Acquisition

Biophama companies are increasingly interested in establishing relationships with  experienced specialty pharmacies to dispense rare disease drugs to patients

PantherRx Rare and Orsini Specialty Pharmacy Chosen as Partners for OXLUMO

Alnylam® Pharmaceuticals selected PantherRx Rare and Orsini Specialty Pharmacy as limited distribution partners for OXLUMO™ (lumasiran). OXLUMO is the first and only treatment approved for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. PH1 is an ultra-rare genetic disease characterized by the overproduction of oxalate, a waste product that […]

Rare Diseases and Orphan Drugs Growth Favorable to Specialty Pharmacies

Biophama companies are increasingly interested in establishing relationships with  experienced specialty pharmacies to dispense rare disease drugs to patients

ACA Supreme Court Deliberations and Any Impact on Biosimilars?

If the court strikes down the ACA entirely, biosimilars on the U.S. market or in the FDA approval pipeline would have to either be grandfathered in or face a regulatory wind-down